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Cross-regulation of β-catenin–LEF/TCF and retinoid signaling
pathways
Vijayasurian Easwaran, Michael Pishvaian, Salimuddin and Stephen Byers
Vitamin A derivatives (retinoids) are potent regulators
of embryogenesis, cell proliferation, epithelial cell
differentiation and carcinogenesis [1]. In breast cancer
cells, the effects of retinoids are associated with
changes in the cadherin–β-catenin adhesion and
signaling system [2,3]. β-catenin is a component of the
Wnt signaling pathway, which regulates several
developmental pathways [4]. Increases in cytoplasmic
β-catenin and β-catenin signaling are also associated
with numerous cancers, and are particularly important
in colon cancer [5]. The oncogenic and developmental
effects of β-catenin are mediated by its interaction with
and activation of members of the LEF/TCF family of
transcription factors [6–8]. Here, we show that retinoic
acid (RA) decreases the activity of the β-catenin–LEF/TCF
signaling pathway. This activity of RA was independent
of the adenomatous polyposis coli (APC) tumor
suppressor and ubiquitination-dependent degradation
of cytoplasmic β-catenin. Consistent with this finding,
β-catenin interacted directly with the RA receptor (RAR)
in a retinoid-dependent manner, but not with the retinoid
X receptor (RXR), and RAR competed with TCF for
β-catenin binding. The activity of RA on RAR-responsive
promoters was also potentiated by β-catenin. The data
suggest that direct regulation of β-catenin–LEF/TCF
signaling is one mechanism whereby RA influences
development, cell differentiation and cancer.
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Results and discussion
Retinoid action is mediated through the retinoid receptor
proteins RAR and RXR, which modulate gene expression
directly, by binding RA-responsive elements (RAREs)
and, indirectly, by inhibiting the activity of other transcrip-
tion factor complexes such as AP-1 [1]. RXR also functions
by heterodimerization with other members of the steroid
hormone receptor superfamily, such as the thyroid
hormone receptor, peroxisome proliferator activator recep-
tor (PPAR) and the vitamin D receptor [9]. Many of the
downstream pathways that mediate retinoid-induced
changes in cells have yet to be defined. Increased cell–cell
adhesion and the recruitment of cytoplasmic β-catenin to
the membrane accompany the effects of 9-cis-RA (9cRA)
on epithelial differentiation [2,3]. In contrast, elevated
cytoplasmic β-catenin levels are associated with Wnt sig-
naling, LEF/TCF-mediated transactivation and oncogene-
sis [6,10–13]. To investigate this potential connection, we
first tested the ability of 9cRA to influence β-catenin sig-
naling activity by measuring β-catenin–LEF/TCF-regu-
lated luciferase reporter activity. We used 9cRA in these
experiments because it can activate RXR homodimers in
addition to RAR–RXR heterodimers. Figure 1a shows
that, in MCF-7 breast cancer cells, which express wild-
type adenomatous polyposis coli (APC), 9cRA reduced
LEF/TCF reporter activity in a dose-dependent manner.
Similar results were obtained with two other cell lines that
are growth inhibited by RA (HS578t and SKBR3 cells;
data not shown).
The β-catenin protein and signaling activity is controlled
by APC-regulated serine phosphorylation and ubiquitin-
dependent protein degradation [5,14]. We next tested
whether the actions of RA on β-catenin–LEF/TCF signal-
ing required APC, and β-catenin ubiquitination. Figure 1b
shows that RA effectively inhibited LEF/TCF reporter
activity in retinoid-sensitive APC-mutant colon cancer
cells (Caco-2) and demonstrates that APC is not required
for RA to inhibit β-catenin–LEF/TCF signaling. Similar
results were obtained in another retinoid-sensitive APC-
mutant cell line HT29 (data not shown). If the actions of
RA involve the targeting of cytoplasmic β-catenin for ubiq-
uitination and proteosomal degradation (in an APC-inde-
pendent manner), one would anticipate that the signaling
activity of stable, non-ubiquitinatable mutants of β-catenin
would not be affected by RA. For example, the signaling
activity of a β-catenin mutant in which the Ser37 residue is
mutated to Ala (S37A) is resistant to inhibition by APC
[14]. In contrast, Figure 1c shows that RA effectively
inhibited LEF/TCF reporter activity induced by the S37A
stable mutant form of β-catenin and further indicates that
the effects of RA are unrelated to events that regulate
β-catenin ubiquitination and proteosomal degradation [15].
Consistent with this, the cytoplasmic pool of β-catenin was
unaffected by RA in Caco-2 cells (Figure 1d). These
results show that, unlike APC and cadherins, the influence
of RA on β-catenin signaling does not require a change in
the signaling pool of β-catenin itself.
To investigate the receptor specificity of vitamin A action
on β-catenin–LEF/TCF signaling, we tested the role of
PPAR and vitamin D receptors, two other steroid receptor
families that are known to influence colon cancer [16].
Caco-2 cells were used in these experiments because they
express PPAR, vitamin D and retinoid receptors, and
respond to all of the cognate ligands [16–18]. Figure 2a
shows that treatment of Caco-2 cells with three different
PPAR ligands did not modulate β-catenin signaling activ-
ity. Vitamin D3 treatment exerted a small but consistent
inhibitory effect on β-catenin signaling activity. In con-
trast, 9cRA (Figure 1) and all-trans-RA markedly decreased
LEF reporter activity. Taken together, these data point
to a direct effect of RA on the regulation of β-catenin–
LEF/TCF-mediated transactivation, potentially mediated
by RAR and/or RXR.
To test whether β-catenin could interact directly with
retinoid receptors, glutathione-S-transferase (GST) ‘pull-
down’ experiments were carried out. Figure 2b shows
that, compared with GST alone, in vitro transcribed and
translated RAR and RXR interacted slightly with a
GST–β-catenin fusion protein. Importantly, the interac-
tion of β-catenin with RAR, but not with RXR, was
markedly increased by RA. The presence of RXR in the
reaction did not inhibit or stimulate β-catenin–RAR inter-
actions (data not shown). These data suggest that, for RA
to regulate β-catenin–LEF/TCF reporter activity, it might
modulate assembly of the β-catenin–LEF/TCF complex.
To test this, we investigated the effects of RA and RAR
on TCF4–β-catenin interactions. Figure 2c shows that, in
the presence of RA, RAR did indeed reduce GST–β-
catenin–TCF interactions. Significant inhibition of TCF4
binding was evident even in the presence of approxi-
mately equimolar amounts of RAR. These results indicate
that RA-activated RAR competes with TCF for binding to
β-catenin in a reaction that does not require RAR het-
erodimerization with RXR.
A direct interaction between β-catenin and RAR
together with the ability of β-catenin to act as a co-activa-
tor for LEF/TCF suggests that β-catenin might regulate
the activity of RAR-responsive promoters. We next
tested the ability of β-catenin to augment the RA stimu-
lation of RA-responsive promoters. Figure 3a shows that
transient transfection of the S37A stable form of
β-catenin into MCF-7 cells increased the activity of the
RA-responsive RARβ promoter. Similar results were
obtained using another RARE reporter but not with an
estrogen-responsive reporter construct (Figure 3b,c).
Like some other co-activators, β-catenin slightly acti-
vated RARE reporters in the absence of RA but this was
always 10% or less of RA-stimulated values (data not
shown). IκBα, the inhibitor of the transcription factor
NFκB, can also interact with retinoid receptors, in this
case with RXR, not RAR [19]. In contrast to β-catenin,
however, IκBα inhibits RXRE reporter activity. Perhaps
the documented ability of the β-catenin carboxyl termi-
nus to recruit the transcriptional machinery allows
RAR–β-catenin heterodimers to transactivate [20].
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Figure 1
(a) Reduction of β-catenin–LEF/TCF signaling
by 9cRA. MCF-7 cells transfected with the
LEF/TCF reporters TOPFlash (optimal
LEF/TCF-binding site) and FOPFlash (mutated
LEF/TCF-binding sites) were treated with
various doses of 9cRA or ethanol for 48 h. The
experiment was repeated at least three times,
with each treatment repeated in triplicate. Error
bars represent standard deviation.
Morphological analysis did not indicate
significant cell death or toxicity. Similar results
were obtained with HS578t and SKBR3 cells.
(b) In APC-mutant Caco-2 cells, 9cRA
decreases β-catenin–LEF/TCF signaling.
Caco-2 cells were transfected with TOPFlash
and FOPFlash and treated with 9cRA for 48 h.
LEF/TCF reporter activity was monitored as
described in the Supplementary material.
Similar results were obtained with APC-mutant
HT29 cells. (c) Signaling induced by wild-type
β-catenin and the S37A non-ubiquitinatable
form of β-catenin is reduced by 9cRA. MCF-7
cells were transfected with vector or wild-type
β-catenin or the S37A mutant of β-catenin,
and the LEF/TCF reporters. Cells were treated
with 10–6 M 9cRA for 48 h. LEF/TCF reporter
activity was monitored as described in the
Supplementary material. (d) In Caco-2 cells,
β-catenin protein levels are not altered by
9cRA. Caco-2 cells were treated with ethanol
or 10–6 M 9cRA for 48 h and either lysed in
sample buffer to make a whole cell lysate
(WCL) or a cytoplasmic fraction (cyt) prepared
as described in the Supplementary material.
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Retinoids are important signaling molecules, both in the
adult and in the developing embryo, and RA can dramati-
cally inhibit the development of anterior structures [21].
Wnt and its Drosophila homologue Wingless are also
important in embryonic patterning, and overexpression of
Wnt-1 or β-catenin in Xenopus results in anterior axis dupli-
cation [7,8,22]. Our demonstration that RA influences
β-catenin–LEF/TCF signaling and that β-catenin influ-
ences RA signaling suggests that these two important
developmental pathways might interact more directly than
previously envisioned. Because increased levels of cyto-
plasmic β-catenin and/or increased β-catenin–LEF/TCF-
signaling can transform cells, we propose that one
mechanism whereby RA inhibits tumorigenesis might be
by directly affecting β-catenin–LEF/TCF transactivation.
If this is true, RA could be considered as a therapeutic
agent for cancers in which β-catenin–LEF/TCF transacti-
vation is overactive. In other studies, we showed that RA
treatment of some breast cancer cells increases cadherin
expression and function [2]. Increased cadherin expression
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Figure 2
(a) Effect of various steroid-receptor-specific
ligands on β-catenin–LEF signaling. Caco-2
cells were transiently transfected with the
LEF/TCF reporters and treated with the
indicated ligands (10–6 M) for 48 h. Three
different PPAR ligands, BRL49653, PGJ2 and
NS398, did not affect LEF/TCF reporter
activity. Vitamin D3 exerted a small but
consistent inhibitory affect. All-trans-RA
(ATRA) markedly inhibited reporter activity.
Reporter activity was measured as described
in the Supplementary material. DMSO,
dimethyl sulphoxide. (b) Interaction of
β-catenin with RAR and RXR. In vitro
transcribed and translated 35S-labeled RARα
and RXRα were incubated, in the absence (–)
or presence (+) of 9cRA (10–6 M), with
glutathione–agarose prebound with GST or
GST–β-catenin for 30 min at 25°C. After
washing, the protein interacting with β-catenin
was eluted by adding 15 mM reduced
glutathione, resolved on 12% gels by
SDS–PAGE and detected using
autoradiography. (c) RARα competes with
TCF4 for binding to GST–β-catenin. Two
TCF4 products were consistently observed
after the transcription and translation reaction.
The β-catenin-binding site of TCF is at the
amino terminus [20]. Because both forms of
TCF4 readily bound β-catenin, it is probable
that the smaller species represents either a
proteolytic product that is missing part of the
carboxyl terminus, or usage of an alternative
termination codon. The binding of both forms
to β-catenin was decreased in the presence of
RAR and RA. Arrows indicate the position of
the in vitro transcribed and translated RAR,
RXR and TCF4.
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Figure 3
RARE-dependent transactivation is
augmented by β-catenin. MCF-7 cells were
transfected with the indicated luciferase (luc)
reporter plasmids and a construct encoding
the S37A mutant form of β-catenin. (a,b) In
the presence of 10–6 M RA, a stable S37A
form of β-catenin augmented the ligand-
induced transactivation of two RARE
reporters ((a) RAREβ and (b) ∆MMTV-
TREpal). (c) In the presence of 10–9 M
estradiol (E2), β-catenin did not augment
ERE-dependent reporter transactivation
(GPB-mERE). See Supplementary material for
a description of the various reporters.
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can also modulate β-catenin signaling, by depleting the
cytoplasmic pool of β-catenin [23,24]. Depending on the
cellular context, therefore, RA can increase the adhesive
function of β-catenin and independently decrease its sig-
naling activity. Taken together with the effects of RA on
other known pathways, we suggest that the pleiotropic and
context-dependent effects of RA result from the differen-
tial regulation of AP-1, RARE and β-catenin–LEF/TCF-
activated transcriptional programs (Figure 4).
Supplementary material
Supplementary material including additional methodological detail is avail-
able at http://current-biology.com/supmat/supmatin.htm.
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Figure 4
Three pathways affected by RA. The ability of RA to influence AP-1
and β-catenin–LEF/TCF signaling depends on RAR but not RXR,
whereas the ability of RA to influence RARE activation requires
RAR–RXR heterodimer formation. The output phenotype then depends
on the genetic program that is activated by the combined effects of
AP-1 and/or β-catenin–LEF/TCF inhibition and RARE activation. The
contribution from each pathway will vary depending on the levels of the
reactants. In colon cancer cells, which have very high levels of
β-catenin, RA-activated RAR might preferentially affect this pathway.
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Supplementary materials and methods
Transfections and reporter assays
To investigate β-catenin–LEF/TCF signaling, cells were transiently trans-
fected as described previously with the LEF/TCF reporters, TOPFlash
(optimal LEF-binding site) and FOPFlash (mutated LEF-binding sites)
[S1,S2]. Data were normalized for transfection efficiency, using pCMV-
Renilla Luciferase and the Dual Luciferase Assay System (Promega). To
investigate RARE and ERE reporter activity, MCF-7 cells were grown in
medium containing 5% charcoal-stripped serum for 36 h (and phenol-
red-free medium for estrogen experiments), and the medium replaced
every 6 h. The following RARE reporter plasmids were used: a fragment
of the RARβ promoter containing the DR5 retinoid-response element
(RAREβ–TK–Luc; [S3]); p∆MMTV–TREpal–Luc, in which the GRE
element was removed from the MMTV promoter and replaced with
TREpal and TREpal–TK–Luc [S4]. The estrogen-responsive promoter,
pGLB–mERE, consists of an ERE in place of the GRE in the MMTV pro-
moter [S5]. Cells were transiently transfected with a RARE-regulated or
ERE-regulated reporter, or control plasmids (TK–Luc; ∆MMTV–Luc;
pGLB–mNON), along with either empty vector or the stable S37A form
of β-catenin using the calcium phosphate method. Following transfec-
tions, cells were maintained in medium containing charcoal-stripped
serum and treated with 10–6 M 9-cis-RA or 10–9 M estrogen or ethanol
for 48 h. Reporter activity was quantified using the Dual Luciferase
Assay System.
Cell fractionation and western blotting
Caco-2 cells were first lysed in hypotonic lysis buffer and ultracen-
trifuged at 100,000 × g for 1 h (cytoplasmic extract) [S6]. The pellet
was extracted in NP-40 lysis buffer (NP-40 soluble). For whole cell
lysates (WCL), cells were directly solublized in SDS sample buffer.
Nuclear extracts were prepared according to established protocols
[S7]. Equal protein was resolved on SDS–PAGE and analyzed by
immunoblot using an anti-β-catenin antibody (Transduction Labs), as
described earlier [S6].
GST pull-down assays
Purified GST or GST–β-catenin (7 nmol) was absorbed onto glu-
tathione–agarose in 1.25 ml binding buffer (20 mM Hepes-KOH
pH 7.4, 50 mM potassium chloride, 1 mM magnesium chloride,
0.1 mg/ml bovine serum albumin) containing 62.5 µl of a 50% slurry of
glutathione–agarose. The agarose beads were washed three times and
resuspended in 250 µl binding buffer. For assay, 20 µl GST–β-catenin-
bound agarose was diluted in 270 µl binding buffer, and then mixed
with 10 µl wheat germ extract containing 35S-labeled translation
product (RAR, RXR or TCF4) for 30 min at 25°C by gentle shaking.
After centrifugation, the supernatant was removed and the beads were
washed once with binding buffer, following which 50 µl 50 mM Tris-
HCl (pH 8.0) containing 15 mM reduced glutathione was added to the
wet agarose beads, the mixture was shaken gently for 1 h at 25°C, and
40 µl of the supernatant was recovered after centrifugation; 20 µl of
the supernatant was resolved by SDS–PAGE on 12% gels and
detected by autoradiography.
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